Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Neuromagen Pharma Logo
Neuromagen Pharma Growth Score
85
CB Rank
647208
Heat Score
61
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.
Founded
obfuscation
Private Be'er Sheva, HaDarom, Israel1-10 www.neuromagen.com/
Biopharma
Biotechnology
Neuroscience
Overview

Neuromagen Pharma
Growth Score
85
Heat Score
61

Growth Score85
-3 pts
in past quarter
Heat Score 61
-23 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Neuromagen Pharma

CB Rank
647208
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.
Founded
obfuscation
Private Be'er Sheva, HaDarom, Israel1-10 www.neuromagen.com/
Biopharma
Biotechnology
Neuroscience

Key People

  • Photo of Gil Ben Menachem
    Gil Ben Menachem: CEO & Co-Founder
    Past Role: Purple Biotech, Vice President of Business Development

Details

Operating Status Active
Company Type For Profit
Founders  Gil Ben Menachem
About the Company
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS. Neuromagen Pharma was founded in 2021 and was headquartered in Beer Sheva, Israel.
Contact Email Info@neuromagen.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

AGS-499
A synthetic small molecule drug candidate that activates Telomerase Reverse Transcriptase (TERT) to delay onset and progression of ALS by protecting motor neurons.
AGS Family of Synthetic Small Molecules
A group of compounds designed to activate TERT transcription to protect neurons and delay neurodegenerative disease progression.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 1

Employee Profiles

News
Technology
View Tech Report

Monthly Web Visits

45

Active Website Tech Count

2Neuromagen Pharma is actively using 2 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible and  CommonCrawl Top 10m.

Total IP

6The intellectual property of Neuromagen Pharma includes 6 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Neuromagen Pharma's headquarters? Neuromagen Pharma is located in Be'er Sheva, HaDarom, Israel.Who are Neuromagen Pharma's competitors? Alternatives and possible competitors to Neuromagen Pharma may include Amylyx Pharmaceuticals, Cytokinetics, and  Ionis Pharmaceuticals.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|